FDA Reclassifies Non-Invasive Bone Growth Stimulators from Class III to Class II (May 2026)
On April 16, 2026, the FDA published a Final Order reclassifying non-invasive bone growth stimulators from Class III (PMA) to Class II (510(k)). The reclassification becomes effective May 18, 2026, giving manufacturers a 30-day window to adjust their regulatory strategy.
If you manufacture or plan to launch a non-invasive bone growth stimulator in the US market, this is a material pathway change. Here's what it means.
The Reclassification in One Table
| Before Apr 2026 | From May 18, 2026 |
|---|---|
| Class III device | Class II device |
| PMA pathway | 510(k) pathway |
| No predicate route (PMA de novo or PMA call) | Predicate-based substantial-equivalence submission |
| Typical cost: $500K–$5M+ | Typical cost: $22K–$500K |
| Typical timeline: 1–3 years | Typical timeline: 6–12 months |
| Clinical investigation typically required | Performance testing + special controls |
Product codes affected: LOF and LPQ (non-invasive bone growth stimulators). Both codified under 21 CFR 890.5870 (Part 890 — Physical Medicine Devices). Product code LOE (invasive bone growth stimulators) is NOT affected — it remains Class III PMA.
Who Is Affected
Manufacturers of:
- Pulsed electromagnetic field (PEMF) bone growth stimulators
- Low-intensity pulsed ultrasound (LIPUS) bone-healing devices
- Other non-invasive external bone-growth-stimulation systems
If your device requires surgical placement (e.g. implantable bone growth stimulators), this reclassification does NOT apply — those remain Class III PMA. The reclassification is strictly for non-invasive external devices.
Why FDA Reclassified
FDA's rationale (summarised from the Federal Register order):
- Sufficient post-market data now exists across the device class to demonstrate that general controls + special controls can provide reasonable assurance of safety and effectiveness.
- Device technology has matured; the predicate landscape is well-established.
- The PMA burden was disproportionate to the residual risk given modern manufacturing and quality standards.
The Final Order codifies seven special controls at 21 CFR 890.5870(b) that Class II submissions must address:
- Clinical data demonstrating intended performance with imaging confirmation of fusion or healing
- Non-clinical performance testing — design outputs, thermal safety, signal characteristics, reliability
- Biocompatibility of patient-contacting components (ISO 10993)
- Electrical safety and EMC testing (IEC 60601-1, IEC 60601-1-2)
- Software verification, validation, and hazard analysis (IEC 62304 alignment recommended)
- Labeling comprehension testing confirming patient can correctly operate the device
- Comprehensive labeling — warnings, clinical summary, instructions for use, maintenance
What Manufacturers Should Do Now (April 17 → May 18)
If you have a device currently in PMA review:
- Contact your FDA reviewer. Options include (a) withdrawing the PMA and filing a 510(k) after May 18, or (b) continuing the PMA if substantially complete.
- The Final Order does not invalidate existing PMA approvals — approved devices stay approved.
If you were planning a Class III submission:
- Pause. After May 18, file a 510(k) with a predicate from the now-reclassified cohort.
- You'll need to identify a predicate device marketed before the reclassification became effective, or rely on one that has cleared under the new 510(k) pathway post-May-18.
If you have a device on the market under 510(k)-exempt or de-novo status:
- No immediate action required, but confirm your regulatory filings reflect the correct classification going forward.
All manufacturers:
- Review your labelling against the new special controls.
- Update your regulatory strategy documents (PRDs, regulatory plans, investor decks).
- If your ROI model assumed PMA burden, recompute — the lower regulatory cost materially improves unit economics for new entrants.
Key Source
- Federal Register Final Order — 91 FR 20352 (Vol. 91 No. 73, April 16, 2026). FR Doc 2026-07366. Docket FDA-2020-N-1053. Effective 2026-05-18. Codified at 21 CFR 890.5870.
- HTML: federalregister.gov/documents/2026/04/16/2026-07366/…
- Official PDF: govinfo.gov/content/pkg/FR-2026-04-16/html/2026-07366.htm
- eCFR (live after effective date): ecfr.gov — 21 CFR Part 890
Why regMD Tracks This
Regulatory classifications change. What was Class III yesterday can be Class II tomorrow, and the pathway cost difference is often 10-20×. If your classification tool (or your regulatory consultant) hasn't been updated, you could spend $1M+ on a PMA that the FDA has just reclassified into a $100K 510(k).
regMD continuously monitors FDA reclassification notices, HSA guidance updates, TGA enforcement priorities, and EU MDR notified-body changes across 14 jurisdictions — so the pathway you see in our tool reflects today's regulation, not last year's.
Last verified: April 17, 2026 against Federal Register Doc 2026-07366. Regulatory classifications can change — always confirm against the current FDA device classification database before submitting.